Latest:
Dr. Robinson on the Updated Results of the KEYNOTE-407 Trial in Squamous NSCLC
Andrew G. Robinson, MD, MSc, FRCPC, discusses the updated results of the phase 3 KEYNOTE-407 trial in squamous non–small cell lung cancer.
Authors
Senthil Damodaran, MD, PhD
Latest:
Dr Damodaran on Futibatinib Plus Fulvestrant in FGFR1-Amplified HR+/HER2– Breast Cancer
Senthil Damodaran, MD, PhD, discusses the efficacy of futibatinib plus fulvestrant in patients with FGFR1-amplified metastatic hormone receptor–positive, HER2-negative breast cancer according to findings from the phase 2 FOENIX-MBC2 trial.
Joseph Barbi, PhD
Latest:
Investigators Seek to Resolve the “Obesity Paradox” in Lung Cancer
Smoking is associated with the most widely known cancer causing carcinogen across the world. However, a second, more insidious factor has been increasingly recognized for its role in promoting cancer growth: obesity.
Joanna M. Rhodes, MD, MSCE
Latest:
Clinical Approaches in Switching Between BTKi’s in R/R CLL & Practical Considerations for Drug Holidays
Panelists discuss how clinical trial data supports switching between different covalent BTK inhibitors for intolerance management, with 60-70% of patients experiencing resolution of the original toxicity.
University of Arizona Cancer Center
Latest:
$10.8M Initiative Unites Engineering and Health Researchers to Improve Cancer Treatments
A University of Arizona project, with funding from the state's New Economy Initiative, creates humanlike cancer models and growth environments to help improve prevention, diagnosis and treatment.